OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. On average, sell-side analysts expect that OncoCyte will post -2.57 EPS for the current year. Insider ...

OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0. ...

13:27 EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holders Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.

OncoCyte Corp (NASDAQ:OCX) launched Graft Assure, a kidney transplant test, with leading transplant centers, enhancing their IVD product development. The company achieved a breakthrough ...

At close: March 28 at 4:00:01 PM EDT ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — OncoCyte Corp. (OCX) on Monday reported a loss of $33.5 million in its fourth quarter. The Irvine, California-based company said it had a loss of $1 ...